M-1211

• CAT Number: I045397
• CAS Number: 2377337-93-2
• Molecular Formula: C42H57FN6O6S
• Molecular Weight: 793.00
• Purity: ≥95%
• Synonyms: methyl N-[(1S,2R)-2-[(1S)-2-(azetidin-1-yl)-1-(3-fluorophenyl)-1-[1-[[3-methoxy-1-[4-[[(1S,4S)-5-prop-2-enoyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]sulfonyl]phenyl]azetidin-3-yl]methyl]piperidin-4-yl]ethyl]cyclopentyl]carbamate
• InChI: InChI=1S/C42H57FN6O6S/c1-4-39(50)48-24-35-23-34(48)25-49(35)56(52,53)36-14-12-33(13-15-36)47-27-41(28-47,55-3)26-46-20-16-30(17-21-46)42(29-45-18-7-19-45,31-8-5-9-32(43)22-31)37-10-6-11-38(37)44-40(51)54-2/h4-5,8-9,12-15,22,30,34-35,37-38H,1,6-7,10-11,16-21,23-29H2,2-3H3,(H,44,51)/t34-,35-,37-,38-,42-/m0/s1
• InChIKey: HFHVSSGMYSWPIR-SZDLQPMWSA-N
• SMILES: COC(=O)NC1CCCC1C(CN2CCC2)(C3CCN(CC3)CC4(CN(C4)C5=CC=C(C=C5)S(=O)(=O)N6CC7CC6CN7C(=O)C=C)OC)C8=CC(=CC=C8)F

M-1211 (Cat No.: I045397) is an investigational monoclonal antibody that targets integrin α5β1, a cell surface receptor involved in tumor growth, angiogenesis, and metastasis. By binding to and inhibiting α5β1 integrin, M-1211 disrupts key signaling pathways that support cancer cell survival and vascular development. It is designed to enhance antitumor effects, either as a monotherapy or in combination with other anticancer agents. M-1211 is primarily being studied in preclinical and early clinical settings for its potential in treating solid tumors and metastatic cancers.

Reference

[1]. Zhang M, et al. Discovery of M-1121 as an Orally Active Covalent Inhibitor of Menin-MLL Interaction Capable of Achieving Complete and Long-Lasting Tumor Regression. J Med Chem. 2021;64(14):10333-10349.
[Content Brief]